VISTA neutralization by immunization reprograms immunosuppression and augments vaccine efficacy in renal carcinoma
Journal for ImmunoTherapy of Cancer · 2026-05 · 14 (5) · e015052
DOI: 10.1136/jitc-2026-015052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 08.05.2026. Verfasst von Jiawei Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Cancer Vaccines, Kidney Neoplasms, Carcinoma, Renal Cell, B7 Antigens. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Province Capability Improvement Project through Science, Technology and Education, Natural Science Research of Jiangsu Higher Education Institutions of China.
Abstract (Originalsprache)
Background
Renal carcinoma remains a highly lethal malignancy, and tumor vaccine efficacy is frequently hampered by a profoundly immunosuppressive tumor microenvironment. V-domain Ig suppressor of T-cell activation (VISTA), an inhibitory immune checkpoint enriched in myeloid cells and regulatory T cells (Tregs), represents a critical barrier to effective antitumor immunity. Targeting VISTA may therefore provide a promising strategy to overcome immune suppression and enhance tumor vaccine efficacy.
Methods
Recombinant adenoviral vaccines encoding carbonic anhydrase IX (CAIX) and VISTA (Ad-CAIX and Ad-VISTA) were constructed and validated for efficient antigen expression. The antitumor efficacy of Ad-VISTA/CAIX co-immunization was evaluated in subcutaneous, lung metastatic, orthotopic, and anti-programmed cell death protein 1-resistant renal carcinoma models. Vaccine-induced immune responses were assessed by flow cytometry, immunohistochemistry, ELISA, cell proliferation assays, cytotoxic T lymphocyte (CTL) assays, and in vivo immune cell depletion experiments.
Results
Ad-VISTA immunization markedly potentiated the therapeutic efficacy of CAIX-targeted vaccination, resulting in significant tumor growth inhibition and prolonged survival across multiple renal carcinoma models. Mechanistically, VISTA-targeting remodeled the tumor microenvironment by enhancing the infiltration and activation of dendritic cells (DCs) and CD8 + T cells while reducing immunosuppressive myeloid cells and Tregs. Ad-VISTA/CAIX co-immunization promoted the expansion and maturation of multiple DC subsets, characterized by increased expression of CD40, CD80, CD86, and major histocompatibility complex molecules, thereby facilitating efficient antigen presentation. VISTA immunization elicited robust antigen-specific antibody and neutralizing responses, restored CD8 + T-cell proliferation, and enhanced CTL-mediated tumor cell killing. Depletion of CD8 + T cells abrogated therapeutic efficacy of Ad-VISTA/CAIX vaccine, establishing its essential role in tumor control. Furthermore, combined vaccination induced durable memory CD8 + T-cell responses capable of preventing tumor recurrence on rechallenge.
Conclusions
These results indicated that vaccine-induced VISTA blockade effectively amplifies DC-mediated CD8 + T-cell immunity and synergistically enhances tumor vaccine efficacy. Targeting VISTA represents a promising immunotherapeutic strategy for improving vaccine-based treatments in renal carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of Oncology, Ninghe District Hospital of Tianjin, Tianjing, China.
- Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of Molecular Oncology and Cancer Biology and Evolution Program, H Lee Moffitt Cancer Center and Research Institute Department of Molecular Oncology, Tampa, Florida, USA.
- Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, Texas, USA chaidafei@xzhmu.edu.cn wangg@xzhmu.edu.cn hui.tian@utsouthwestern.edu.
Förderung
- National Natural Science Foundation of China
- Jiangsu Province Capability Improvement Project through Science, Technology and Education
- Natural Science Research of Jiangsu Higher Education Institutions of China
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Wang, J., Wang, Z., Zhao, W., Chen, H., Lu, B., Shao, Y., Zheng, Y., Liu, S., Wang, M., Fang, L., Li, H., Neeli, P., Tian, H., Wang, G., & Chai, D. (2026). VISTA neutralization by immunization reprograms immunosuppression and augments vaccine efficacy in renal carcinoma. Journal for ImmunoTherapy of Cancer, 14(5), e015052. https://doi.org/10.1136/jitc-2026-015052
Vancouver
Wang J, Wang Z, Zhao W, Chen H, Lu B, Shao Y, et al. VISTA neutralization by immunization reprograms immunosuppression and augments vaccine efficacy in renal carcinoma. Journal for ImmunoTherapy of Cancer. 2026;14(5):e015052. doi:10.1136/jitc-2026-015052
BibTeX
@article{Wang2026,
author = {Wang, Jiawei and Wang, Zhenzhen and Zhao, Wanting and Chen, Haomin and Lu, Bowen and Shao, Yingxiang and Zheng, Yanyan and Liu, Shanshan and Wang, Meng and Fang, Lin and Li, Huizhong and Neeli, Praveen and Tian, Hui and Wang, Gang and Chai, Dafei},
title = {VISTA neutralization by immunization reprograms immunosuppression and augments vaccine efficacy in renal carcinoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {5},
pages = {e015052},
doi = {10.1136/jitc-2026-015052}
}
EUVIMED